Scientific Reports (Jan 2022)

MAFLD progression contributes to altered thalamus metabolism and brain structure

  • Saverio Nucera,
  • Stefano Ruga,
  • Antonio Cardamone,
  • Anna Rita Coppoletta,
  • Lorenza Guarnieri,
  • Maria Caterina Zito,
  • Francesca Bosco,
  • Roberta Macrì,
  • Federica Scarano,
  • Miriam Scicchitano,
  • Jessica Maiuolo,
  • Cristina Carresi,
  • Rocco Mollace,
  • Luca Cariati,
  • Giuseppe Mazzarella,
  • Ernesto Palma,
  • Micaela Gliozzi,
  • Vincenzo Musolino,
  • Giuseppe Lucio Cascini,
  • Vincenzo Mollace

DOI
https://doi.org/10.1038/s41598-022-05228-5
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Metabolic associated fatty liver disease (MAFLD), commonly known as non-alcoholic fatty liver disease, represents a continuum of events characterized by excessive hepatic fat accumulation which can progress to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and in some severe cases hepatocellular carcinoma. MAFLD might be considered as a multisystem disease that affects not only the liver but involves wider implications, relating to several organs and systems, the brain included. The present study aims to investigate changes associated with MAFLD-induced alteration of thalamic metabolism in vivo. DIAMOND (Diet-induced animal model of non-alcoholic fatty liver disease) mice were fed a chow diet and tap water (NC NW) or fat Western Diet (WD SW) for up to 28 weeks. At the baseline and weeks 4, 8, 20, 28 the thalamic neurochemical profile and total cerebral brain volume were evaluated longitudinally in both diet groups using 1H-MRS. To confirm the disease progression, at each time point, a subgroup of animals was sacrificed, the livers excised and placed in formalin. Liver histology was assessed and reviewed by an expert liver pathologist. MAFLD development significantly increases the thalamic levels of total N-acetylaspartate, total creatine, total choline, and taurine. Furthermore, in the WD SW group a reduction in total cerebral brain volume has been observed (p < 0.05 vs NC NW). Our results suggest that thalamic energy metabolism is affected by MAFLD progression. This metabolic imbalance, that is quantifiable by 1H-MRS in vivo, might cause structural damage to brain cells and dysfunctions of neurotransmitter release.